Skip to main content
. 2017 Apr 24;13(6):5035. doi: 10.3892/ol.2017.6082

Figure 2.

Figure 2.

Survival data for patients with metastatic urothelial carcinoma treated with vinflunine as second-line chemotherapy, illustrated by Kaplan-Meier curves. (A) mPFS of 2.8 months (range, 0.5–34.3 months) and (B) mOS of 6.3 months (range, 0.3–39.7 months). mPFS, median progression-free survival; mOS, median overall survival.